
Why Halozyme Therapeutics is the Biotech Stock to Watch Now
Biotech stocks are volatile, influenced by FDA trial outcomes and therapy demand. Halozyme Therapeutics shines with its Enhaze platform, enabling subcutaneous drug delivery using the rHuPH20 enzyme. This technology improves drug absorption and patient comfort, offering a competitive advantage. In Q3 2024,